Kornimate/medical-research-clean huggingface dataset:
tonabersat in the prophylaxis of migraine with aura

Conditions: Migraine With Aura

Summary: overall trial objectives: 1. can treatment with tonabersat reduce the number of days with aura and/or migraine headache in patients with migraine with aura 2. how well tolerated is treatment with tonabersat the study is based on the hypothesis that the unique mechanism of action of tonabersat will inhibit some of the early events in the generation of aura and migraine headache and so be effective as prophylactic treatment


Eligibility criteria:
inclusion criteria: * patients with an established history of migraine of at least one year meeting the diagnostic criteria of the international classification of headache disorders - edition 2 (appendix 2) and who experience at least one aura a month. * male or female patients between 18-65 years of age * women of child bearing potential must be using a reliable form of contraception (defined in the protocol) for at least 3 months prior to enrolment and they must have a negative pregnancy test at screening with no intention of becoming pregnant during the study period exclusion criteria: * patients experiencing headache other than migraine or tension headache * overuse of acute migraine treatments defined as more than 14 daily doses per month with analgesics or more than 9 daily doses per month of ergots or triptans within the last two months * migraine prophylactic treatment within two months prior to entry to the trial * patients taking any of the following medications for migraine: beta-blockers, tricyclic antidepressants (during the last 2 months), antiepileptic dugs (during the last 2 months), calcium channel blockers, monoamine oxidase inhibitors, daily nsaids, daily paracetamol, high dose magnesium supplements (600mg/day). parenteral administration of botulinum toxin is also excluded. these drugs are permitted when given for diseases other than migraine provided that, in the opinion of the investigator the dose can be kept constant throughout the trial. * patients who, in the opinion of the investigator, have significant cerebrovascular disease e.g. transient ischaemic attacks, stroke * patients who, in the opinion of the investigator, have clinically significant cardiovascular disease * patients suffering from a current clinical diagnosis of a major depressive disorder or schizophrenia * patients with renal dysfunction , defined as a serum creatinine of greater than 125% of the upper limit of normal for their age group * patients with hepatic dysfunction defined as a liver function test (ast, alt, alkaline phosphatase, bilirubin) of greater than twice the upper limit of normal for their age group * patients with known alcohol or other substance abuse * use of an investigational drug (for any indication) within 30 days or 5 half-lives, whichever is the longer, prior to screening * women who are pregnant or breast feeding * women of childbearing potential not using a reliable form of contraception * patients with any other clinically significant condition which, in the investigators opinion, would render them unsuitable for this study
non-invasive evaluation program for tips and follow up network

Conditions: Portal Hypertension

Summary: evaluation of non-invasive prognostic parameters in patients receiving transjugular intrahepatic portosystemic shunt (tips) for complications of portal hypertension. patients are cared according to the local standardized follow up program. clinical and laboratory data from standard patient care are evaluated for potential prognostic value.

neptun consists of liver cirrhosis receiving transjugular intrahepatic portosystemic shunt (tips) at the department of internal medicine i, university of bonn, germany and receiving a structured routine evaluation and follow up program. the diagnosis of cirrhosis was based on clinical, hemodynamic and biochemical parameters, and ultrasound and/or biopsy criteria.

Eligibility criteria:
inclusion criteria: * insertion of tips according to guidelines exclusion criteria: * contraindication for tips

Keywords: transjugular intrahepatic portosystemic shunt (tips) non-invasive assessments transthoracic echocardiography (tte) with speckle-tracking computer tomography scan (ct-scan) magnetic resonance imaging (mri) circulating biomarkers electroencephalography (eeg)
algerian cholecystectomy outcomes and determinants study (al-cods)

Conditions: Cholecystectomy; Adults; Gall Stone; Polyps; Pancreatitis Biliary; Gallbladder Dyskinesia; Cholecystitis

Summary: cholecystectomy, the surgical removal of the gallbladder, is a common procedure performed to treat benign gallbladder diseases such as cholelithiasis (gallstones), cholecystitis (inflammation of the gallbladder), and biliary dyskinesia. while generally considered safe, this surgery can be associated with significant morbidity and mortality, particularly in certain populations or healthcare settings. understanding these outcomes and the factors influencing them is crucial for improving patient care and surgical practices. in algeria, the healthcare landscape presents unique challenges and opportunities for evaluating surgical outcomes. limited studies have specifically focused on the morbidity and mortality associated with cholecystectomy in this context. this study aims to fill that gap by providing comprehensive data on 30-day postoperative outcomes following cholecystectomy for benign gallbladder diseases in algeria. such data is essential for benchmarking current practices, identifying areas for improvement, and ultimately enhancing patient safety and surgical efficacy.

this study seeks to bridge this knowledge gap by offering detailed data on 30-day postoperative outcomes after cholecystectomy for benign gallbladder diseases in algeria. this information is crucial for benchmarking existing practices, pinpointing areas for enhancement, and ultimately improving patient safety and surgical effectiveness.

Eligibility criteria:
inclusion criteria: * patients aged 18 years and older. * undergoing cholecystectomy. * surgery performed in public or private hospitals in algeria. * surgery performed from january 1, 2025, to june 30, 2025. exclusion criteria: * patients younger than 18 years. * patients refusing to participate. * cholecystectomy performed for gallbladder cancer. * cholecystectomy performed outside the inclusion period. * cholecystectomies performed in conjunction with other major surgeries.

Keywords: algeria cholecystectomy mortality morbidity 30 days determinants
phase 1/2 study evaluating safety and potential efficacy of allocetra-ots via pressurized intra-peritoneal aerosol chemotherapy as add-on to standard of care chemotherapy for treatment of peritoneal metastasis

Conditions: Peritoneal Metastases

Summary: this is an open-label study to evaluate safety and potential efficacy of allocetra-ots in the treatment of patients with peritoneal metastasis as an add-on to the standard of care (soc) chemotherapy.

pressurized intra-peritoneal aerosol chemotherapy (pipac) is utilized in patients with malignant dissemination to the peritoneal cavity, for the treatment of peritoneal metastasis that have a high tumor burden or are unresectable, and are unresponsive to systemic therapy. allocetra-ots is an immunomodulatory cell-based therapy consisting of allogeneic peripheral blood mononuclear cells that have been modified to be engulfed by macrophages and reprogram them into their homeostatic state. the study will evaluate the safety and potential efficacy of allocetra-ots in the treatment of peritoneal metastasis as an add-on to the standard of care (soc) chemotherapy. patients will be treated with escalating doses of allocetra-ots as an add-on to the chemotherapy administered via pipac, and in addition to systemic chemotherapy.

Eligibility criteria:
inclusion criteria: * 18 years of age or older. * diagnosis of peritoneal metastasis due to any primary tumor by histopathology or cytology * possession of unresectable tumors (not eligible for cytoreductive surgery / hyperthermic intra-peritoneal chemoperfusion crs/hipec). * adequate performance status and surgical risk * adequate hematopoietic, hepatic and renal function exclusion criteria: * extraperitoneal disease. * bowel obstruction * history of liver cirrhosis with child pugh classification of b or c or signs of portal hypertension, portal vein thrombosis. * patient with known new york heart association (nyha) class 3 or 4 symptomatic congestive heart failure, severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias. * previous history of organ allograft or stem cell transplantation.
the effect of rtem in the prognosis and severity of sepsis induced ards

Conditions: Sepsis

Summary: to observe the changes of plasma rtem levels in patients with sepsis, sepsis induced ards, and to explore its clinical significance.

90 patients will be included in this study. blood samples from these patients in the first day, the third day, were maintained and tested to detect the change of rtem level. severity of illness and survival status of every patient were recorded within 28 days. the objective is to observe the changes of plasma rtem levels in patients with sepsis, sepsis induced ards, and to explore its clinical significance.

Eligibility criteria:
inclusion criteria: diagnosed as sepsis 3.0 patients signing informed consent exclusion criteria: pregnant women patients with tumor、hepatitis、liver cirrhosis、acute myocardial infarction、chronic renal tubular nephritis、interstitial pneumonia、acute pancreatitis、systemic lupus erythenatosus、ulcerative colitis、crohn's disease、hellp syndrome
the effect of continuous glucose monitoring on glycemic control and pregnancy outcomes in gestational diabetes mellitus

Conditions: Gestational Diabetes; Continuous Glucose Monitoring

Summary: the purpose of this study is to determine if continuous glucose monitoring improves glycemic control and pregnancy outcomes of gestational diabetes mellitus

gestational diabetes mellitus (gdm) is defined as any degree of glucose intolerance that is first identified during pregnancy, excluding diabetic patients diagnosed before pregnancy. the purpose of this study is to determine if continuous glucose monitoring improves glycemic control and pregnancy outcomes of gestational diabetes mellitus.

Eligibility criteria:
inclusion criteria: * women with gestational diabetes * 18-45 years old * 24-28 weeks gestation of pregnancy * singleton pregnancy * bmi≥18kg/m2 exclusion criteria: * pregestational type 1 or 2 diabetes mellitus * aged \ 45 years * bmi\<18kg/m2 * multiple pregnancy * cushing's syndrome/ using exogenous steroids * chronic infection ( hiv, hepatitis b/c, tuberculosis) * any active chronic systemic disease ( except essential hypertension) * severe liver and kidney dysfunction

Keywords: gestational diabetes continuous glucose monitoring glycemic control
ultrasound-guided stellate ganglion block for treatment of chronic migraine in adult

Conditions: Chronic Migraine

Summary: to assess the 6-months effects and safety of stellate ganglion block(sgb) for chronic migraine (cm) patients who failure to undergo preventive therapy and are seeking a more suitable non-pharmacological therapy.

the investigators aim to investigate whether the stellate ganglion block(sgb) is better than traditional medication treatment and provides medical evidence for the clinical application and promotion of sgb to provide a minimally invasive, safe, and effective treatment for patients with chronic migraine(cm) who failed to receive standardized drug treatment.

Eligibility criteria:
inclusion criteria: 1. age from 18 to 65 years; 2. diagnosed with cm according to the international classification of headache disorders, 3rd (ichd-3) criteria \[headache classification committee of the international headache society (ihs). the international classification of headache disorders, 3rd edition. cephalalgia. 2018;38:1-211\]. 3. not received prior prophylactic migraine treatment or, due to lack of efficacy or tolerability, had failed or had not been suitable for up to three previous prophylactic treatments from the following: metoprolol/propranolol, amitriptyline, and flunarizine. exclusion criteria: 1. bmi \ 35 kg/m2； 2. previous sgb treatment； 3. history of other neurological disorders； 4. history of severe cardiopulmonary, hepatic or renal dysfunction； 5. history of allergies to any of the study drugs； 6. patients with chronic use of opioids； 7. preoperative coagulation abnormalities (activated partial thromboplastin time greater than 1.5 time normal value)； 8. infection or mass near the puncture site； 9. neck anatomic structural changes (caused by radiotherapy or surgery); 10. pregnant or breast feeding; 11. psychological disorders; 12. refusal to sign informed consent.

Keywords: chronic migraine stellate ganglion block
luteal phase support in insemination cycles

Conditions: Infertility, Female

Summary: this study is a prospective randomized trial with 242 iui cycles. patients are randomized in two groups including 121 cycles in each group. a total of 255 cycles in 167 patients are finally recruited. in the first group, the patients will be treated with triptorelin (gonapeptyl®) in their luteal phase. as for the other group, the patients will undergo the luteal phase without any supportive medication. this study is going to clarify the role of the gonadotropin agonist (triptorelin acetate, gonapeptyl®) as a luteal phase supporter. the benefit of the treatment is measured by the numbers in the live birth and clinical pregnancy rates.


Eligibility criteria:
inclusion criteria: * - patients with ovarian stimulation cycles preparing to insemination * patients with medical ovarian stimulation protocols including gnrh agonist, aromatase inhibitors and different combinations of gnrh agonists and aromatase inhibitors are included * patient's willingness to participate in the study exclusion criteria: * - failure in the ovarian stimulation cycle * failures in executing the insemination * failures in giving the sperm sample * major troubles in sperm parameters leading to an inadequate sample to accomplish intrauterine insemination * patients with primarily planned progesterone luteal support

Keywords: insemination luteal phase support gonadotropin-releasing hormone agonist triptorelin
cdiag regimen in the treatment of relapsed or refractory acute myeloid leukemia

Conditions: Acute Myeloid Leukemia, Relapsed, Adult

Summary: this study is to investigate the therapeutic efficacy and side effect of chidamide, decitabine combined with priming iag regimen for relapsed or refractroy acute myeloid leukemia


Eligibility criteria:
inclusion criteria: * relapsed or refractory acute myeloid leukemia patients without severe complications such as active infections and bleedings; ecog score less than 3. exclusion criteria: * inablity to tolerate inducton chemotherapy; life expectancy less than 1 month

Keywords: chidamide decitabine priming regimen
vaginal progesterone improves clinical outcomes of rif patients

Conditions: Infertility, Female

Summary: this study is a single-center, randomized, controlled prospective study. those patients with repeated implantation failure (rif) who will recieve frozen thawed embryo transfer (fet) are enrolled in the study. to determine the effect of vaginal progesterone on the clinical pregnancy outcomes of rif patients.

according to the enrollment and exclusion criteria, the patients were enrolled, and the subjects were randomly divided into two groups by computer randomization. group a was the vaginal progesterone added group (test group). group b was the regular fet group (control group).

Eligibility criteria:
inclusion criteria: 1. aged between 20 and 40 years old; 2. bmi: 18-28 kg/m2； 3. consistent with the diagnosis of repeated implantation failure of unknown reasons, the previous embryo transfer situation meets one of the following: total embryos transferred ≥ 4 high-quality cleavage-stage embryos; ≥ 2 blastocysts; ≥ 2 high quality cleavage-stage embryos +≥ 1 blastocysts; 4. at least 1 high-quality embryo remained for embryo transfer; 5. volunteer to participate in the study and sign the informed consent form. exclusion criteria: 1. patients with recurrent pregnancy loss (≥ 2 biochemical pregnancies or ≥ 2 spontaneous abortions); 2. adverse pregnancy history (stillbirth, fetal malformation, etc.); 3. severe paternal factors: need for tesa or pesa; 4. pgt; 5. failure of embryo implantation due to any definite reason, including but not limited to: endometrial adhesion (moderate to severe), thin endometrium (\ 4.0 cm and/or endometrial compression), reproductive malformation, serious immune disease, serious coagulation function abnormality; 6. chromosome abnormality of either spouse; 7. those with contraindications to pregnancy or assisted reproductive technology.
a study of avastin (bevacizumab) plus xeloda (capecitabine) in patients with locally advanced rectal cancer.

Conditions: Colorectal Cancer

Summary: this open-label study will assess the efficacy and safety of avastin (bevacizumab) plus xeloda (capecitabine) in combination with standard technique radiotherapy of the pelvic region in the neo-adjuvant setting in patients with locally advanced primary rectal cancer. patients will receive 4 courses of avastin at a dose of 5 mg/kg intravenously (iv) every 2 weeks and for 38 days xeloda at dose of 825 mg/kg twice daily orally, plus radiation therapy. after surgery, adjuvant treatment with 5-fluorouracil/leucovorin and, at the discretion of the investigator, with avastin 5 mg/kg iv every 2 weeks for at least 6 months will be given.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age * patients with confirmed rectal cancer who are subject to surgery and would benefit from pre-operative combined chemo-radiotherapy * measurable and/or evaluable lesions according to recist criteria * eocg performance status 0-1 exclusion criteria: * prior radiotherapy or chemotherapy for rectal cancer * untreated brain metastases or spinal cord compression or primary brain tumors * chronic daily treatment with high-dose aspirin (\>325 mg/day) or other medications known to predispose to gastrointestinal ulceration * co-existing malignancies, or malignancies diagnosed within the last 5 years, with the exception of basal and squamous cell cancer, or cervical cancer in situ.
an educational hiv pre-test counseling video program for off hours testing in the ed: a randomized control trial

Conditions: HIV Counseling and Testing; HIV Infections

Summary: this study compared the educational effectiveness of a ten-minute pre-test counseling video with the usual practice of a session with an hiv counselor.

hiv is increasingly affecting urban populations, making the inner city ed a prime venue for c\&t because of their unique opportunity to identify hiv positive patients. these underserved communities often use the ed for their regular health care specifically because it provides services outside of the usual weekday working hours. however, there are significant barriers to hiv c\&t in the ed, such as the lack of resources to provide prevention oriented messages, cost issues, and the feasibility of providing the required manpower for testing. the objective of this study is to determine whether an educational video, with the required pre-test counseling elements, conveys the necessary information for inner city ed patients to consent to a standard elisa hiv test. in order to address the hiv testing needs of the patient population presenting to the ed, innovative methods must be developed to provide hiv c\&t, while simultaneously removing the barriers to testing. video technology may provide an opportunity to make hiv counseling feasible when counselors are not available.

Eligibility criteria:
inclusion criteria: * all patients awaiting uc treatment were approached for the study. * patients 18 years of age and older were included * patients who spoke english and spanish were included. exclusion criteria: * clinically unstable, * diagnosed with hiv * unable to understand the consent process because such patients require unique arrangements for consenting processes.

Keywords: hiv prevention hiv counseling hiv testing emergency medicine hiv seronegativity
surgical / economic effect of the aquamantys system in blood management for aseptic and septic revision tka

Conditions: Infection of Total Knee Joint Prosthesis; Aseptic Loosening of Prosthetic Joint

Summary: to assess the surgical and economic effectiveness of the aquamantys system in managing intra- and post-operative blood loss, and reducing transfusion needs in patients undergoing both aseptic and septic revision total knee arthroplasty.

the use of the saline-coupled bipolar sealing technology (aquamantys® system, medtronic advanced energy, llc, portsmouth, nh, usa) represents a modern approach to reducing perioperative blood loss in patients undergoing total joint arthroplasty. unlike standard electrocautery, which use monopolar radiofrequency energy, this technology uses bipolar radiofrequency energy combined with a continuous-flow saline at the electrode tip to prevent tissue temperatures from exceeding 100 °c thus minimizing tissue charring. this eliminates the smoke and eschar formation seen with standard electrocautery. the temperature achieved is sufficient to induce a process called transcollation(tm) which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue. suction is used to remove the saline from the surgical field with the treated tissue turning a light tan color. with normal use, the depth of penetration of this effect is typically less than 2mm. the technology is cleared by the us fda (510(k)) and eu (ce mark) for use on soft tissue \& bone and will be used according to its intended packaging indications for use. the current assessment proposes a technique in which a disposable aquamantys® hand piece is used to treat targeted areas which are bleeding or expected to bleed during surgery. this postmarket study will assess the surgical and economic effectiveness of aquamantys® system in managing intra-operative blood loss and transfusion rates in patients undergoing septic and aseptic revision tka.

Eligibility criteria:
inclusion criteria * the patient is greater than 18 years of age * patients following failure of primary, unilateral tka * the degree of revision requires the use of an extended osteotomy for component removal * patient has participated in the informed consent process and has signed an ethics committee approved informed consent exclusion criteria * patients presenting with a history of bleeding disorders and/or are on chronic blood anticoagulation therapy * patients presenting with an internal cardiac defibrillator * women who are pregnant * prisoner or transient * recent history of known narcotic abuse * any significant psychological disturbance past or present, that could impair the consent process or ability to complete subject self-report questionnaires * subject unwilling to undergo blood transfusion, if necessary

Keywords: revision tka septic aseptic transfusion blood loss